ONO-4059 analog

CAS No. 1351635-67-0

ONO-4059 analog( ONO 4059 analog | ONO4059 analog )

Catalog No. M11421 CAS No. 1351635-67-0

A highly potent and selective Btk inhibitor with IC50 in the sub-nM range; analog of ONO-4059.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 92 In Stock
2MG 51 In Stock
5MG 85 In Stock
10MG 140 In Stock
25MG 278 In Stock
50MG 453 In Stock
100MG 647 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ONO-4059 analog
  • Note
    Research use only, not for human use.
  • Brief Description
    A highly potent and selective Btk inhibitor with IC50 in the sub-nM range; analog of ONO-4059.
  • Description
    A highly potent and selective Btk inhibitor with IC50 in the sub-nM range; analog of ONO-4059.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ONO 4059 analog | ONO4059 analog
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    BTK
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1351635-67-0
  • Formula Weight
    456.4965
  • Molecular Formula
    C25H24N6O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 29 mg/mL
  • SMILES
    C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
  • Chemical Name
    8H-Purin-8-one, 6-amino-7,9-dihydro-9-[(3S)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl]-7-(4-phenoxyphenyl)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yamamoto, et al. WO 2011152351 A1 20111208.
molnova catalog
related products
  • Poseltinib

    Poseltinib (HM-71224, LY-3337641) is a potent and selective, covalent inhibitor of Btk with IC50 of 1.95 nM.

  • Acalabrutinib enanti...

    Acalabrutinib enantiomer (R-Acalabrutinib) is a chemical compound that belongs to the class of Bruton’s tyrosine kinase (BTK) inhibitors.

  • Pirtobrutinib

    Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations.